Image
user avatar
Caribou Biosciences
@CaribouBio
Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases
Berkeley, CA
cariboubio.com
Joined July 2014
207
Following
6,611
Followers
Posts
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Sep 8, 2020
    Thrilled to announce that the @FDA has cleared Caribou’s first IND for a CRISPR #genome-edited off-the-shelf allogeneic anti-CD19 CAR-T #celltherapy candidate for patients with relapsed/refractory B cell non-Hodgkin #lymphoma. Read more here: bit.ly/2F0cbvr
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Jul 23, 2021
    Excited to share that Caribou is now publicly listed on @nasdaq as $CRBU! We look forward to progressing our scientific innovations in chRDNA-edited allogeneic cell therapies to transform the lives of patients living with devastating diseases.
    Image
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Jul 6, 2023
    We are pleased to announce @pfizer has invested $25M in Caribou as part of the Pfizer Breakthrough Growth Initiative (PBGI), a program focused on funding promising clinical development programs of potential future strategic interest to Pfizer.
    Image
    5.8K
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Apr 4, 2024
    $CRBU is expanding clinical development of CB-010 into #autoimmunedisease. We have received IND clearance from the @US_FDA for CB-010 in lupus nephritis and extrarenal lupus. More details on the GALLOP Phase 1 trial here: bit.ly/4am15dy #Lupus #autoimmune #CRISPR
    Image
    00:00
    7K
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Oct 18, 2023
    We are proud to announce FDA clearance of the IND application for CB-012, our allogeneic anti-CLL-1 CAR-T cell therapy for r/r #AML. Read more about the CB-012 AMpLify Phase 1 trial here: investor.cariboubio.com/news-releases/… #leukemia
    Image
    8.6K
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Jul 12, 2021
    Thrilled to announce that the first patient has been dosed in our phase 1 clinical trial to evaluate a differentiated #CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma. Learn more: bwnews.pr/3e8ubSB
    Image
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Dec 12, 2023
    We are pleased to announce we have received feedback from the FDA following a Type B meeting for the CB-010 Phase 3 pivotal trial. Read today’s press release for full details: bit.ly/3v065Vy
    Image
    2.6K
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Feb 12, 2024
    Prior to evaluating CB-011 in the ongoing CaMMouflage clinical trial, the $CRBU team investigated the impact of our immune cloaking strategy in preclinical models. Read the full analysis here: bit.ly/4bzdD22 #CRISPR
    2.8K
  • user avatar
    Caribou Biosciences
    @CaribouBio
    May 12, 2022
    Excited to announce we are scheduled to share positive initial data for our ANTLER Phase 1 #clinicaltrial of CB-010 at #EHA2022, demonstrating a generally well tolerated safety profile & a 100% ORR & 80% CR in r/r B-NHL patients. Read more: bit.ly/3yrZzGG
    Image
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Nov 21, 2022
    We’re excited to announce the U.S. #FDA has cleared our IND application for CB-011, our anti-BCMA #CARTcelltherapy with immune cloaking for r/r #multiplemyeloma and we look forward to initiating patient enrollment for the CaMMouflage trial in early 2023. bit.ly/3XirT8h
    Image
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Apr 9, 2024
    Our poster presentation from #AACR2024 featuring preclinical, IND-enabling data from CB-012, our allogeneic anti-CLL-1 #CART cell therapy for the treatment of relapsed or refractory acute myeloid #leukemia, is now available for viewing on our website: bit.ly/49q55bG
    Image
    9.5K
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Jul 13, 2023
    We are excited to announce that data from the 16 patients enrolled in dose escalation for the CB-010 ANTLER trial rival that of approved autologous #CARTcelltherapies. Read more here: bit.ly/3NUfP9x
    Image
    2.8K
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Mar 5, 2024
    Preclinical data from CB-012, our allogeneic anti-CLL-1 CAR-T #celltherapy for the treatment of relapsed or refractory acute myeloid #leukemia, will be presented at #AACR24 in San Diego. Read today’s press release for full details: bit.ly/4a26Oo3 $CRBU @AACR
    Image
    3.3K
  • user avatar
    Caribou Biosciences
    @CaribouBio
    Jun 10, 2022
    We are excited to share additional data from our ANTLER Phase 1 #clinicaltrial today at #EHA2022, showing CB-010 as the 1st allogeneic CAR-T #celltherapy to achieve a 100% CR rate as best response for all 6 patients. To learn more, watch our webcast here: bit.ly/38LLxFr
    Image